| Date:         | Mar. 25 <sup>th</sup> ,2022 |   |
|---------------|-----------------------------|---|
| Your Name:    | Zhihua Li                   |   |
| Manuscript Ti | tle:Therapeutic pot         | ential of anti-miR29a in breast cancer patients with type 2 diabetes: |
|               | an in vitro and             | xenograft mouse-model study   |
| Manuscript no | umber (if known):           |   |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |                               | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|-------------------------------|--|---|
|   |                               | Time frame: Since the initial  | planning of the work  |
| 1 | All support for the present   | XNone  |   |
|   | manuscript (e.g., funding,    |  |   |
|   | provision of study materials, |  |   |
|   | medical writing, article      |  |   |
|   | processing charges, etc.)     |  |   |
|   | No time limit for this item.  |  |   |
|   |                               |  |   |
|   |                               |  |   |
|   |                               | Time frame: past   | 36 months   |
| 2 | Grants or contracts from      | XNone  |   |
|   | any entity (if not indicated  |  |   |
|   | in item #1 above).            |  |   |
| 3 | Royalties or licenses         | _XNone   |   |
|   |                               |  |   |
|   |                               |  |   |
| 4 | Consulting fees               | _XNone   |   |
|   |                               |  |   |

| 5   | Payment or honoraria for lectures, presentations,                     | _XNone |  |  |  |  |
|-----|---|--------|--|--|--|--|
|     |   |        |  |  |  |  |
|     | speakers bureaus,   |        |  |  |  |  |
|     | manuscript writing or   |        |  |  |  |  |
|     | educational events  |        |  |  |  |  |
| 6   | Payment for expert  | _XNone |  |  |  |  |
|     | testimony   |        |  |  |  |  |
| -   | 6 16 11 1:  | V N    |  |  |  |  |
| 7   | Support for attending meetings and/or travel                          | _XNone |  |  |  |  |
|     |   |        |  |  |  |  |
|     |   |        |  |  |  |  |
| 8   | Patents planned, issued or  | _XNone |  |  |  |  |
|     | pending   |        |  |  |  |  |
|     |   |        |  |  |  |  |
| 9   | Participation on a Data   | _XNone |  |  |  |  |
|     | Safety Monitoring Board or  |        |  |  |  |  |
|     | Advisory Board  |        |  |  |  |  |
| 10  | Leadership or fiduciary role  | _XNone |  |  |  |  |
|     | in other board, society,  |        |  |  |  |  |
|     | committee or advocacy   |        |  |  |  |  |
| 11  | group, paid or unpaid Stock or stock options                          | V Nene |  |  |  |  |
| 11  | Stock or Stock options  | _XNone |  |  |  |  |
|     |   |        |  |  |  |  |
| 12  | Receipt of equipment,   | X None |  |  |  |  |
|     | materials, drugs, medical   |        |  |  |  |  |
|     | writing, gifts or other   |        |  |  |  |  |
|     | services  |        |  |  |  |  |
| 13  | Other financial or non-   | _XNone |  |  |  |  |
|     | financial interests   |        |  |  |  |  |
|     |   |        |  |  |  |  |
|     |   |        |  |  |  |  |
|     |   |        |  |  |  |  |
| Ple | Please summarize the above conflict of interest in the following box: |        |  |  |  |  |

| None. |  |  |
|-------|--|--|
|       |  |  |
|       |  |  |
|       |  |  |
|       |  |  |

| Date:         | Mar. 25 <sup>th</sup> ,2022 |   |
|---------------|-----------------------------|---|
| Your Name:_   | Liangliang Min_             |   |
| Manuscript Ti | itle:Therapeutic pot        | ential of anti-miR29a in breast cancer patients with type 2 diabetes: |
|               | an in vitro and             | xenograft mouse-model study   |
| Manuscript n  | umber (if known):           |   |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |   | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|--|---|
|   |   | Time frame: Since the initial  | planning of the work  |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item. | XNone  |   |
|   |   | Time frame: past   | 36 months   |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above).  | XNone  |   |
| 3 | Royalties or licenses   | _XNone   |   |
| 4 | Consulting fees   | _XNone   |   |

| 5   | Payment or honoraria for  | _XNone |  |  |  |  |
|-----|---|--------|--|--|--|--|
|     | lectures, presentations,  |        |  |  |  |  |
|     | speakers bureaus,   |        |  |  |  |  |
|     | manuscript writing or   |        |  |  |  |  |
|     | educational events  |        |  |  |  |  |
| 6   | Payment for expert  | _XNone |  |  |  |  |
|     | testimony   |        |  |  |  |  |
|     |   |        |  |  |  |  |
| 7   | Support for attending meetings and/or travel                          | _XNone |  |  |  |  |
|     | meetings and/or traver  |        |  |  |  |  |
|     |   |        |  |  |  |  |
|     |   |        |  |  |  |  |
| 8   | Patents planned, issued or  | _XNone |  |  |  |  |
|     | pending   |        |  |  |  |  |
|     |   |        |  |  |  |  |
| 9   | Participation on a Data   | _XNone |  |  |  |  |
|     | Safety Monitoring Board or  |        |  |  |  |  |
|     | Advisory Board  |        |  |  |  |  |
| 10  | Leadership or fiduciary role  | _XNone |  |  |  |  |
|     | in other board, society,  |        |  |  |  |  |
|     | committee or advocacy   |        |  |  |  |  |
|     | group, paid or unpaid   |        |  |  |  |  |
| 11  | Stock or stock options  | _XNone |  |  |  |  |
|     |   |        |  |  |  |  |
|     |   |        |  |  |  |  |
| 12  | Receipt of equipment,   | _XNone |  |  |  |  |
|     | materials, drugs, medical   |        |  |  |  |  |
|     | writing, gifts or other services                                      |        |  |  |  |  |
| 13  | Other financial or non-   | _XNone |  |  |  |  |
|     | financial interests   |        |  |  |  |  |
|     |   |        |  |  |  |  |
|     |   |        |  |  |  |  |
|     |   |        |  |  |  |  |
| Ple | Please summarize the above conflict of interest in the following box: |        |  |  |  |  |

| None. |  |  |  |
|-------|--|--|--|
|       |  |  |  |
|       |  |  |  |
|       |  |  |  |
|       |  |  |  |

| Date:            | Mar. 25 <sup>th</sup> ,2022   |
|------------------|---|
| Your Name:       | _Lu Chen  |
| Manuscript Title | :Therapeutic potential of anti-miR29a in breast cancer patients with type 2 diabetes: |
|                  | an in vitro and xenograft mouse-model study   |
| Manuscript num   | ber (if known):   |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |   | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|--|---|
|   |   | Time frame: Since the initia   | planning of the work  |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item. | XNone  |   |
|   |   | Time frame: past   | 36 months   |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above).  | XNone  |   |
| 3 | Royalties or licenses   | _XNone   |   |
| 4 | Consulting fees   | _XNone   |   |

| 5   | Payment or honoraria for  | _XNone |  |  |  |  |
|-----|---|--------|--|--|--|--|
|     | lectures, presentations,  |        |  |  |  |  |
|     | speakers bureaus,   |        |  |  |  |  |
|     | manuscript writing or   |        |  |  |  |  |
|     | educational events  |        |  |  |  |  |
| 6   | Payment for expert  | _XNone |  |  |  |  |
|     | testimony   |        |  |  |  |  |
|     |   |        |  |  |  |  |
| 7   | Support for attending meetings and/or travel                          | _XNone |  |  |  |  |
|     | meetings and/or traver  |        |  |  |  |  |
|     |   |        |  |  |  |  |
|     |   |        |  |  |  |  |
| 8   | Patents planned, issued or  | _XNone |  |  |  |  |
|     | pending   |        |  |  |  |  |
|     |   |        |  |  |  |  |
| 9   | Participation on a Data   | _XNone |  |  |  |  |
|     | Safety Monitoring Board or  |        |  |  |  |  |
|     | Advisory Board  |        |  |  |  |  |
| 10  | Leadership or fiduciary role  | _XNone |  |  |  |  |
|     | in other board, society,  |        |  |  |  |  |
|     | committee or advocacy   |        |  |  |  |  |
|     | group, paid or unpaid   |        |  |  |  |  |
| 11  | Stock or stock options  | _XNone |  |  |  |  |
|     |   |        |  |  |  |  |
|     |   |        |  |  |  |  |
| 12  | Receipt of equipment,   | _XNone |  |  |  |  |
|     | materials, drugs, medical   |        |  |  |  |  |
|     | writing, gifts or other services                                      |        |  |  |  |  |
| 13  | Other financial or non-   | _XNone |  |  |  |  |
|     | financial interests   |        |  |  |  |  |
|     |   |        |  |  |  |  |
|     |   |        |  |  |  |  |
|     |   |        |  |  |  |  |
| Ple | Please summarize the above conflict of interest in the following box: |        |  |  |  |  |

| None. |  |  |  |
|-------|--|--|--|
|       |  |  |  |
|       |  |  |  |
|       |  |  |  |
|       |  |  |  |

| Date:      | Mar. 25 <sup>th</sup> ,2022   |  |
|------------|---|--|
| Your Name: | Yangyang Hu   |  |
| Manuscript | Title: Therapeutic potential of anti-miR29a in breast cancer patients with type 2 diabetes: |  |
|            | an in vitro and xenograft mouse-model study   |  |
| Manuscript | number (if known):  |  |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |   | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|--|---|
|   | _   | Time frame: Since the initial  | planning of the work  |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item. | XNone  |   |
|   |   | Time frame: past   | 36 months   |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above).  | XNone  |   |
| 3 | Royalties or licenses   | _XNone   |   |
| 4 | Consulting fees   | _XNone   |   |

|     |   | ,       | · |  |  |
|-----|---|---------|---|--|--|
|     |   |         |   |  |  |
| 5   | Payment or honoraria for  | _XNone  |   |  |  |
|     | lectures, presentations,  |         |   |  |  |
|     | speakers bureaus,   |         |   |  |  |
|     | manuscript writing or   |         |   |  |  |
|     | educational events  |         |   |  |  |
| 6   | Payment for expert  | _XNone  |   |  |  |
|     | testimony   |         |   |  |  |
| _   |   |         |   |  |  |
| 7   | Support for attending meetings and/or travel                          | _XNone  |   |  |  |
|     |   |         |   |  |  |
|     |   |         |   |  |  |
| 8   | Patents planned, issued or  | _XNone  |   |  |  |
|     | pending   |         |   |  |  |
|     |   |         |   |  |  |
| 9   | Participation on a Data   | _XNone  |   |  |  |
|     | Safety Monitoring Board or  |         |   |  |  |
|     | Advisory Board  |         |   |  |  |
| 10  | Leadership or fiduciary role  | _XNone  |   |  |  |
|     | in other board, society,  |         |   |  |  |
|     | committee or advocacy   |         |   |  |  |
| 44  | group, paid or unpaid   |         |   |  |  |
| 11  | Stock or stock options  | _XNone  |   |  |  |
|     |   |         |   |  |  |
| 12  | Pacaint of aguinment  | X None  |   |  |  |
| 12  | Receipt of equipment, materials, drugs, medical                       | _^NUILE |   |  |  |
|     | writing, gifts or other   |         |   |  |  |
|     | services  |         |   |  |  |
| 13  | Other financial or non-   | _XNone  |   |  |  |
|     | financial interests   | -       |   |  |  |
|     |   |         |   |  |  |
| Ple | Please summarize the above conflict of interest in the following box: |         |   |  |  |

| None. |  |  |  |
|-------|--|--|--|
|       |  |  |  |
|       |  |  |  |
|       |  |  |  |
|       |  |  |  |

| Date:                  | _Mar. 25 <sup>th</sup> ,2022   |
|------------------------|--|
| Your Name:             | Wenjing Luan   |
| <b>Manuscript Titl</b> | e:Therapeutic potential of anti-miR29a in breast cancer patients with type 2 diabetes: |
|                        | an in vitro and xenograft mouse-model study  |
| Manuscript nui         | mber (if known):   |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |   | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|--|---|
|   |   | Time frame: Since the initia   | planning of the work  |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item. | XNone  |   |
|   |   | Time frame: past   | 36 months   |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above).  | XNone  |   |
| 3 | Royalties or licenses   | _XNone   |   |
| 4 | Consulting fees   | _XNone   |   |

|     |   | T      | · |  |  |
|-----|---|--------|---|--|--|
|     |   |        |   |  |  |
| 5   | Payment or honoraria for  | _XNone |   |  |  |
|     | lectures, presentations,  |        |   |  |  |
|     | speakers bureaus,   |        |   |  |  |
|     | manuscript writing or   |        |   |  |  |
|     | educational events  |        |   |  |  |
| 6   | Payment for expert  | _XNone |   |  |  |
|     | testimony   |        |   |  |  |
|     |   |        |   |  |  |
| 7   | Support for attending meetings and/or travel                          | _XNone |   |  |  |
|     |   |        |   |  |  |
|     |   |        |   |  |  |
| 8   | Patents planned, issued or  | _XNone |   |  |  |
|     | pending   |        |   |  |  |
|     |   |        |   |  |  |
| 9   | Participation on a Data   | _XNone |   |  |  |
|     | Safety Monitoring Board or  |        |   |  |  |
|     | Advisory Board  |        |   |  |  |
| 10  | Leadership or fiduciary role  | _XNone |   |  |  |
|     | in other board, society,  |        |   |  |  |
|     | committee or advocacy   |        |   |  |  |
|     | group, paid or unpaid   |        |   |  |  |
| 11  | Stock or stock options  | _XNone |   |  |  |
|     |   |        |   |  |  |
| 4.5 |   |        |   |  |  |
| 12  | Receipt of equipment,   | _XNone |   |  |  |
|     | materials, drugs, medical   |        |   |  |  |
|     | writing, gifts or other services                                      |        |   |  |  |
| 13  | Other financial or non-   | _XNone |   |  |  |
|     | financial interests   |        |   |  |  |
|     |   |        |   |  |  |
|     |   |        |   |  |  |
|     |   |        |   |  |  |
| pام | Please summarize the above conflict of interest in the following boy: |        |   |  |  |

| None. |  |  |
|-------|--|--|
|       |  |  |
|       |  |  |
|       |  |  |
|       |  |  |

| Date:         | Mar. 25 <sup>th</sup> ,2022  |           |
|---------------|--|-----------|
| Your Name:    | Cong Li_   | _         |
| Manuscript Ti | :Therapeutic potential of anti-miR29a in breast cancer patients with type 2 diabetes | <u>::</u> |
|               | an in vitro and xenograft mouse-model study  |           |
| Manuscript nu | ber (if known):  |           |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |   | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|--|---|
|   |   | Time frame: Since the initial  | planning of the work  |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item. | XNone  |   |
|   |   | Time frame: past   | 36 months   |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above).  | XNone  |   |
| 3 | Royalties or licenses   | _XNone   |   |
| 4 | Consulting fees   | _XNone   |   |

| 5   | Payment or honoraria for  | _XNone |  |  |  |
|-----|---|--------|--|--|--|
|     | lectures, presentations,  |        |  |  |  |
|     | speakers bureaus,   |        |  |  |  |
|     | manuscript writing or   |        |  |  |  |
|     | educational events  |        |  |  |  |
| 6   | Payment for expert  | _XNone |  |  |  |
|     | testimony   |        |  |  |  |
|     |   |        |  |  |  |
| 7   | Support for attending meetings and/or travel                          | _XNone |  |  |  |
|     | meetings and/or traver  |        |  |  |  |
|     |   |        |  |  |  |
|     |   |        |  |  |  |
| 8   | Patents planned, issued or  | _XNone |  |  |  |
|     | pending   |        |  |  |  |
|     |   |        |  |  |  |
| 9   | Participation on a Data   | _XNone |  |  |  |
|     | Safety Monitoring Board or  |        |  |  |  |
|     | Advisory Board  |        |  |  |  |
| 10  | Leadership or fiduciary role  | _XNone |  |  |  |
|     | in other board, society,  |        |  |  |  |
|     | committee or advocacy   |        |  |  |  |
|     | group, paid or unpaid   |        |  |  |  |
| 11  | Stock or stock options  | _XNone |  |  |  |
|     |   |        |  |  |  |
|     |   |        |  |  |  |
| 12  | Receipt of equipment,   | _XNone |  |  |  |
|     | materials, drugs, medical   |        |  |  |  |
|     | writing, gifts or other services                                      |        |  |  |  |
| 13  | Other financial or non-   | _XNone |  |  |  |
|     | financial interests   |        |  |  |  |
|     |   |        |  |  |  |
|     |   |        |  |  |  |
|     |   |        |  |  |  |
| Ple | Please summarize the above conflict of interest in the following box: |        |  |  |  |

| None. |  |  |  |
|-------|--|--|--|
|       |  |  |  |
|       |  |  |  |
|       |  |  |  |
|       |  |  |  |

| Date:        | Mar. 25 <sup>th</sup> ,2022 |  |
|--------------|-----------------------------|--|
| Your Name:_  | Qiuyun Xiong                |  |
| Manuscript T | itle:Therapeutic po         | tential of anti-miR29a in breast cancer patients with type 2 diabetes: |
|              | an in vitro and             | xenograft mouse-model study  |
| Manuscript n | umber (if known):           |  |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |                               | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|-------------------------------|--|---|
|   |                               | Time frame: Since the initial  | planning of the work  |
| 1 | All support for the present   | XNone  |   |
|   | manuscript (e.g., funding,    |  |   |
|   | provision of study materials, |  |   |
|   | medical writing, article      |  |   |
|   | processing charges, etc.)     |  |   |
|   | No time limit for this item.  |  |   |
|   |                               |  |   |
|   |                               |  |   |
|   |                               | Time frame: past   | 36 months   |
| 2 | Grants or contracts from      | XNone  |   |
|   | any entity (if not indicated  |  |   |
|   | in item #1 above).            |  |   |
| 3 | Royalties or licenses         | _XNone   |   |
|   |                               |  |   |
|   |                               |  |   |
| 4 | Consulting fees               | _XNone   |   |
|   |                               |  |   |

| 5   | Payment or honoraria for lectures, presentations,                       | _XNone                        |               |
|-----|---|-------------------------------|---------------|
|     |   |                               |               |
|     | speakers bureaus,   |                               |               |
|     | manuscript writing or   |                               |               |
|     | educational events  |                               |               |
| 6   | Payment for expert  | _XNone                        |               |
|     | testimony   |                               |               |
|     |   |                               |               |
| 7   | Support for attending   | _XNone                        |               |
|     | meetings and/or travel  |                               |               |
|     |   |                               |               |
|     |   |                               |               |
|     |   |                               |               |
|     |   |                               |               |
| 8   | Patents planned, issued or  | _XNone                        |               |
|     | pending   |                               |               |
|     |   |                               |               |
| 9   | Participation on a Data<br>Safety Monitoring Board or<br>Advisory Board | _XNone                        |               |
|     |   |                               |               |
|     |   |                               |               |
| 10  | Leadership or fiduciary role  | _XNone                        |               |
|     | in other board, society,  |                               |               |
|     | committee or advocacy   |                               |               |
|     | group, paid or unpaid   |                               |               |
| 11  | Stock or stock options  | X None                        |               |
|     | •   |                               |               |
|     |   |                               |               |
| 12  | Receipt of equipment,   | X None                        |               |
|     | materials, drugs, medical writing, gifts or other                       |                               |               |
|     |   |                               |               |
|     | services  |                               |               |
| 13  | Other financial or non-   | X None                        |               |
|     | financial interests   |                               |               |
|     |   |                               |               |
|     |   |                               |               |
|     |   |                               |               |
| Ple | ease summarize the above c  | onflict of interest in the fo | allowing hox: |

| None. |  |  |
|-------|--|--|
|       |  |  |
|       |  |  |
|       |  |  |
|       |  |  |

| Date:                         | Mar. 26 <sup>th</sup> ,2022_ |   |  |  |  |
|-------------------------------|------------------------------|---|--|--|--|
| Your Name:                    | Kedi Huang_                  |   |  |  |  |
| Manuscript Ti                 | itle:Therapeutic po          | stential of anti-miR29a in breast cancer patients with type 2 diabetes: |  |  |  |
|                               | an in vitro and              | d xenograft mouse-model study   |  |  |  |
| Manuscript number (if known): |                              |   |  |  |  |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |   | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|--|---|
|   | _   | Time frame: Since the initial  | planning of the work  |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item. | XNone  |   |
|   |   | Time frame: past   | 36 months   |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above).  | XNone  |   |
| 3 | Royalties or licenses   | _XNone   |   |
| 4 | Consulting fees   | _XNone   |   |

| Г   | Down out on her aresis fare                         | V None                                |              |  |  |  |
|-----|---|---------------------------------------|--------------|--|--|--|
| Э   | 5 Payment or honoraria for lectures, presentations, | _XNone                                |              |  |  |  |
|     |   |                                       |              |  |  |  |
|     | speakers bureaus,                                   |                                       |              |  |  |  |
|     | manuscript writing or                               |                                       |              |  |  |  |
|     | educational events                                  | V N                                   |              |  |  |  |
| 6   | Payment for expert                                  | _XNone                                |              |  |  |  |
|     | testimony   |                                       |              |  |  |  |
| _   |   | , , , , , , , , , , , , , , , , , , , |              |  |  |  |
| 7   | Support for attending                               | _XNone                                |              |  |  |  |
|     | meetings and/or travel                              |                                       |              |  |  |  |
|     |   |                                       |              |  |  |  |
|     |   |                                       |              |  |  |  |
|     |   |                                       |              |  |  |  |
| 8   | Patents planned, issued or                          | _XNone                                |              |  |  |  |
|     | pending   |                                       |              |  |  |  |
|     |   |                                       |              |  |  |  |
| 9   | Participation on a Data                             | _XNone                                |              |  |  |  |
|     | Safety Monitoring Board or                          |                                       |              |  |  |  |
|     | Advisory Board                                      |                                       |              |  |  |  |
| 10  | Leadership or fiduciary role                        | X None                                |              |  |  |  |
|     | in other board, society,                            |                                       |              |  |  |  |
|     | committee or advocacy                               |                                       |              |  |  |  |
|     | group, paid or unpaid                               |                                       |              |  |  |  |
| 11  | Stock or stock options                              | _XNone                                |              |  |  |  |
|     |   |                                       |              |  |  |  |
|     |   |                                       |              |  |  |  |
| 12  | Receipt of equipment,<br>materials, drugs, medical  | _XNone                                |              |  |  |  |
|     |   |                                       |              |  |  |  |
|     | writing, gifts or other                             |                                       |              |  |  |  |
|     | services  |                                       |              |  |  |  |
| 13  | Other financial or non-                             | _XNone                                |              |  |  |  |
|     | financial interests                                 |                                       |              |  |  |  |
|     |   |                                       |              |  |  |  |
|     |   |                                       |              |  |  |  |
|     |   |                                       |              |  |  |  |
| Ple | ease summarize the above c                          | onflict of interest in the fo         | llowing box: |  |  |  |
|     |   |                                       |              |  |  |  |

| None. |  |  |  |
|-------|--|--|--|
|       |  |  |  |
|       |  |  |  |
|       |  |  |  |
|       |  |  |  |